The ATLAS Study: A Clinical Trial for Adults with a Confirmed SOD1 Mutation without Symptoms of ALS

This 30-minute presentation provides an overview of the ATLAS study, the investigational drug, eligibility criteria, and what study participation involves. The presentation also includes resources for interested individuals to learn more about study participation. The webinar is presented by Michael Benatar, MD, PhD; he is the Professor of Neurology, the Walter Bradley Chair in ALS Research, and Executive Director of the ALS Center at the University of Miami.
This information is not intended to replace discussions with your healthcare provider. This Industry Update Webinar is sponsored by Biogen. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.